NO20001514L - Vitronectin receptor antagonist - Google Patents

Vitronectin receptor antagonist

Info

Publication number
NO20001514L
NO20001514L NO20001514A NO20001514A NO20001514L NO 20001514 L NO20001514 L NO 20001514L NO 20001514 A NO20001514 A NO 20001514A NO 20001514 A NO20001514 A NO 20001514A NO 20001514 L NO20001514 L NO 20001514L
Authority
NO
Norway
Prior art keywords
receptor antagonist
vitronectin receptor
vitronectin
osteoporosis
useful
Prior art date
Application number
NO20001514A
Other languages
Norwegian (no)
Other versions
NO20001514D0 (en
Inventor
Dirk Andries Heerding
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO20001514D0 publication Critical patent/NO20001514D0/en
Publication of NO20001514L publication Critical patent/NO20001514L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

En forbindelse med formel (I) er beskrevet, som er en vitronectin-reseptor- antagonist og er nyttig for behandling av osteoporose, eller et farmasøytisk godtagbart salt derav.A compound of formula (I) is disclosed which is a vitronectin receptor antagonist and useful for the treatment of osteoporosis, or a pharmaceutically acceptable salt thereof.

NO20001514A 1997-09-24 2000-03-23 Vitronectin receptor antagonist NO20001514L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5983297P 1997-09-24 1997-09-24
PCT/US1998/019949 WO1999015170A1 (en) 1997-09-24 1998-09-24 Vitronectin receptor antagonist

Publications (2)

Publication Number Publication Date
NO20001514D0 NO20001514D0 (en) 2000-03-23
NO20001514L true NO20001514L (en) 2000-03-23

Family

ID=22025570

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001514A NO20001514L (en) 1997-09-24 2000-03-23 Vitronectin receptor antagonist

Country Status (13)

Country Link
EP (1) EP1017387A4 (en)
JP (1) JP2002528380A (en)
KR (1) KR20010024247A (en)
CN (1) CN1273529A (en)
AU (1) AU9577498A (en)
BR (1) BR9813208A (en)
CA (1) CA2303846A1 (en)
HU (1) HUP0003949A2 (en)
IL (1) IL135189A0 (en)
NO (1) NO20001514L (en)
PL (1) PL339413A1 (en)
TR (1) TR200000792T2 (en)
WO (1) WO1999015170A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002536370A (en) 1999-02-03 2002-10-29 メルク エンド カムパニー インコーポレーテッド Benzoazepine derivatives as α-V integrin receptor antagonists
US6514964B1 (en) * 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
JP2004521079A (en) * 2000-08-29 2004-07-15 ファルマシア・コーポレーション Compounds containing bicyclic ring systems useful as alpha vbeta3 antagonists
US6531494B1 (en) 2001-08-29 2003-03-11 Pharmacia Corporation Gem-substituted αvβ3 antagonists
WO2002018340A1 (en) * 2000-08-30 2002-03-07 Pharmacia Corporation GEM-SUBSTITUTED α v β 3 INTEGRIN ANTAGONISTS
KR100861466B1 (en) 2001-04-24 2008-10-02 메르크 파텐트 게엠베하 Combination therapy using anti-angiogenic agents and tnf?
JP4750360B2 (en) 2001-10-22 2011-08-17 ザ スクリプス リサーチ インスティチュート Antibody targeting compounds
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
JP2009523813A (en) 2006-01-18 2009-06-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Specific therapies using integrin ligands to treat cancer
KR20090108713A (en) 2007-01-18 2009-10-16 메르크 파텐트 게엠베하 Specific therapy and medicament using integrin ligands for treating cancer
JP5359879B2 (en) * 2007-11-16 2013-12-04 宇部興産株式会社 Benzazepinone compounds
US8076475B2 (en) * 2008-03-06 2011-12-13 Glaxosmithkline Llc Process
JP2012517447A (en) 2009-02-10 2012-08-02 ザ スクリプス リサーチ インスティチュート Chemically programmed vaccination methods
EP2415474B1 (en) 2009-03-30 2013-08-28 Ube Industries, Ltd. Pharmaceutical composition for treatment or prevention of ophthalmic diseases
JP5572996B2 (en) * 2009-05-15 2014-08-20 宇部興産株式会社 Medicine containing benzazepinone compound as active ingredient
NZ597339A (en) 2009-05-25 2013-10-25 Merck Patent Gmbh Continuous administration of cilengitide in cancer treatments
CN103864765B (en) * 2014-03-05 2016-02-10 天津药物研究院 Benzazepine analog derivative containing five-membered ring, Preparation Method And The Use
CN106572997A (en) 2014-05-30 2017-04-19 辉瑞公司 Carbonitrile derivatives as selective androgen receptor modulators
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996000574A1 (en) * 1994-06-29 1996-01-11 Smithkline Beecham Corporation Vitronectin receptor antagonists
UA60311C2 (en) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Vitronectin receptor antagonists
WO1998015278A1 (en) * 1996-10-07 1998-04-16 Smithkline Beecham Corporation Method for stimulating bone formation

Also Published As

Publication number Publication date
NO20001514D0 (en) 2000-03-23
KR20010024247A (en) 2001-03-26
JP2002528380A (en) 2002-09-03
PL339413A1 (en) 2000-12-18
IL135189A0 (en) 2001-05-20
HUP0003949A2 (en) 2001-10-28
TR200000792T2 (en) 2000-09-21
WO1999015170A1 (en) 1999-04-01
CN1273529A (en) 2000-11-15
CA2303846A1 (en) 1999-04-01
EP1017387A1 (en) 2000-07-12
BR9813208A (en) 2000-08-22
EP1017387A4 (en) 2004-08-18
AU9577498A (en) 1999-04-12

Similar Documents

Publication Publication Date Title
NO20001514L (en) Vitronectin receptor antagonist
NO983002L (en) Vitronectin receptor antagonists
NO20001515L (en) Vitronectin receptor antagonist
TR200000812T2 (en) 2-methyl-thieno-benzodiazepine formulation.
NO20025821L (en) 2-aminocarbonyl-9H-purine
GB0111523D0 (en) Chemical compounds
NO20021328L (en) Pyrazolopyrimidia as therapeutic agents
TR199801253T2 (en) Vitronectin receptor antagonists.
PT923554E (en) N-BENZYLPIPERIDINE AND TETRAHYDROPYRIDINE DERIVATIVES
NO975975L (en) Vitronectin receptor antagonists, preparation and use thereof
DE60121461D1 (en) CONDENSED PYRIDOINDOL DERIVATIVES
BR9812340A (en) Vitronectin receptor antagonists
DE69722004D1 (en) nucleotide analogs
DE69935873D1 (en) 2-Methyl-thieno-benzodiazepine formulation
NO973652D0 (en) 5- (4-Subst. Piperidinyl-1) -3-aryl pentanoic acid and derivatives as tachykinin receptor antagonist
NO974400L (en) Combination preparations containing benazepril or benazeprilat and valsartan
AP1534A (en) Vitronectin receptor antagonists.
NO20014855L (en) N- (2-phenyl-4-aminobutyl) -1-naphthamides as neurokinin-1 receptor antagonists
NO963331L (en) 5-Heteroarylindole derivatives as benzodiazepine receptor site agonists and antagonists
TWI255813B (en) Compounds for use as alphavbeta3 receptor antagonists
WO2000007544A3 (en) Vitronectin receptor antagonists
PT855398E (en) SASQUITERPENE DERIVATIVES HAVING ANTIVIRAL ACTIVITY
HUP0100540A2 (en) Substituted oximes as neurokinin antagonists
DK0850225T3 (en) Intermediate for the preparation of a pharmaceutically active compound

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application